Project Grant 2507367
Award Date 10/1/25
Completion Date 9/30/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fayetteville, AR 72764, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) SBIR Phase I Project Grant award of $305,000.00 to Absco Therapeutics, Inc. aims to develop an image-guided intratumoral therapy for treating immunotherapy-resistant solid tumors, a $125 billion market. The project seeks to create an innovative drug delivery platform that can improve the efficacy and reduce the toxicity of biological cancer therapies by enhancing on-target delivery and controlling...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop an automated system that streamlines the preparation of liquid biopsy samples for cancer testing. The $305,000 award, provided to Avant Genomics, LLC, will fund the creation of a microfluidic-based system that automates the bisulfite conversion process, a critical step in epigenetic analysis of circulating tumor DNA. This innovation seeks...
- This Small Business Innovation Research (SBIR) Phase I project, awarded by the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, is intended to develop new artificial intelligence (AI) models that can comprehend and utilize formal causal logic. The goal is to create AI models that are more trustworthy, accurate, and reliable than existing AI approaches, particularly for healthcare applications. The $304,929 award to Causalit LLC will fund the...
- This SBIR Phase I grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $303,864 to Core Biotherapeutics, Inc. to develop a platform for discovering disruptive drug candidates that can address high unmet medical needs. The project aims to determine the biological laws of molecular networks driving diseases and program these into an efficient, scalable algorithm for drug target discovery. The goal is to enable the rapid design and...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I SBIR grant awarded $305,000.00 to Redpoint Oncology, Inc. on June 1, 2025 to develop a novel platform for targeted cancer therapies. The project aims to create new cancer treatments designed to target and destroy cancer cells, addressing the critical unmet need for effective therapies that can overcome therapy resistance, which leads to approximately 90% of cancer deaths. The platform is...
- This SBIR Phase I federal grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $305,000 to Plexymer, Inc. to develop an AI-directed automation platform for accelerated bioformulation of antibody therapeutics. The project aims to streamline the process of transitioning hospital-administered antibody infusions to self-administered subcutaneous injections, potentially reducing formulation time and material use by up to 50%. By...
- This $1,236,522 cooperative agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of an advanced web portal for artificial intelligence (AI)-based comprehensive discovery of repositioning drugs for cancer treatment. The project aims to build the CATOS-AI (Cancer Treatment Optimization Solutions - Artificial Intelligence) platform, which will leverage machine learning and multi-omics analysis to...
- The National Science Foundation (NSF) awarded a $305,000 Phase I Small Business Innovation Research (SBIR) grant to Sostos Inc., a minority-owned, woman-owned small disadvantaged business, to develop a cloud-based software platform for identifying multi-omics biomarkers critical for guiding non-small cell lung cancer treatment decisions. The project aims to deliver a user-friendly web-based interface that will enable oncologists to select optimal treatments and assess biomarker applicability...
- This $274,990 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of a physics-based machine learning platform for predicting the crystal structure of small drug molecules. The technology aims to accelerate and reduce the cost of early-stage pharmaceutical research and development by computationally analyzing the crystal structure properties that determine key...
- This $1,213,619 Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a precision oncology platform by Encapsulate Inc., a small disadvantaged business located in Farmington, CT. The project aims to create an integrated microfluidic system that utilizes patient-derived tumor samples to predict individual responses to cancer treatments, including chemotherapy drugs. By maintaining...